Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Rain Oncology Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 11:20 a.m. ET, virtually. Rain is focused on developing precision oncology therapeutics, particularly its lead candidate, milademetan, which inhibits the MDM2-p53 complex to reactivate p53. The presentation will be available via live webcast, with a replay accessible later on the Rain website. Rain is also advancing a preclinical program aimed at inducing synthetic lethality in cancer cells through RAD52 inhibition.

NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be presenting a corporate overview at the Oppenheimer 33^rd Annual Healthcare Conference on Monday, March 13, 2023, at 11:20 a.m. ET, in a virtual format.

A live webcast of the presentation can be accessed here. A replay of the event will be available on the “Events” section of the Rain website after the conclusion of the event and will be archived on the Rain website at www.rainoncology.com.

About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of the MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com        

FAQ

When is Rain Oncology's presentation at the Oppenheimer Healthcare Conference?

Rain Oncology's presentation is scheduled for March 13, 2023, at 11:20 a.m. ET.

What is the primary focus of Rain Oncology Inc.?

Rain Oncology focuses on developing precision oncology therapeutics, targeting oncogenic drivers in cancer.

What is milademetan, Rain's lead product candidate?

Milademetan is an oral small molecule inhibitor of the MDM2-p53 complex that aims to reactivate p53.

How can I access the live webcast of Rain's corporate overview?

The live webcast can be accessed through Rain's website during the presentation.

Will a replay of Rain's presentation be available?

Yes, a replay will be available on the Rain website after the event.